Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Carboplatin + Paclitaxel + Pembrolizumab + Olaparib	455
Overall Study	STARTED	Carboplatin + Paclitaxel + Pembrolizumab	458
Overall Study	STARTED	Carboplatin + Paclitaxel	454
Overall Study	Treated	Carboplatin + Paclitaxel + Pembrolizumab + Olaparib	452
Overall Study	Treated	Carboplatin + Paclitaxel + Pembrolizumab	456
Overall Study	Treated	Carboplatin + Paclitaxel	454
Overall Study	COMPLETED	Carboplatin + Paclitaxel + Pembrolizumab + Olaparib	0
Overall Study	COMPLETED	Carboplatin + Paclitaxel + Pembrolizumab	0
Overall Study	COMPLETED	Carboplatin + Paclitaxel	0
Overall Study	NOT COMPLETED	Carboplatin + Paclitaxel + Pembrolizumab + Olaparib	455
Overall Study	NOT COMPLETED	Carboplatin + Paclitaxel + Pembrolizumab	458
Overall Study	NOT COMPLETED	Carboplatin + Paclitaxel	454

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03740165/flow